Adaptive designs for subpopulation analysis optimizing utility functions
暂无分享,去创建一个
[1] Daniel J Sargent,et al. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Gabriel,et al. On closed testing procedures with special reference to ordered analysis of variance , 1976 .
[3] Boris Freidlin,et al. Randomized clinical trials with biomarkers: design issues. , 2010, Journal of the National Cancer Institute.
[4] Lei Shen,et al. A Statistical Framework for Decision Making in Confirmatory Multipopulation Tailoring Clinical Trials , 2012 .
[5] B. Freidlin,et al. Biomarker enrichment strategies: matching trial design to biomarker credentials , 2014, Nature Reviews Clinical Oncology.
[6] George Y H Chi,et al. A method for testing a prespecified subgroup in clinical trials , 2007, Statistics in medicine.
[7] Baldur P Magnusson,et al. Group sequential enrichment design incorporating subgroup selection , 2013, Statistics in medicine.
[8] Frank Bretz,et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.
[9] M Kieser,et al. Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.
[10] Tt Nguyen,et al. Willingness to Pay For A Quality-Adjusted Life Year of Outpatients with Cardiovascular Diseases , 2016 .
[11] W. Lehmacher,et al. Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.
[12] Armin Koch,et al. Personalized medicine using DNA biomarkers: a review , 2012, Human Genetics.
[13] C. Jennison,et al. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.
[14] P. Bauer,et al. Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.
[15] Robert A. Beckman,et al. Integrating predictive biomarkers and classifiers into oncology clinical development programmes , 2011, Nature Reviews Drug Discovery.
[16] Cyrus Mehta,et al. Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies , 2009, Circulation.
[17] Mohammad F Huque,et al. A flexible strategy for testing subgroups and overall population , 2009, Statistics in medicine.
[18] R. Simon,et al. Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients , 2005, Clinical Cancer Research.
[19] Martin Posch,et al. Optimal choice of the number of treatments to be included in a clinical trial , 2009, Statistics in medicine.
[20] Sue-Jane Wang,et al. Adaptive patient enrichment designs in therapeutic trials , 2009, Biometrical journal. Biometrische Zeitschrift.
[21] Michael E. Chernew,et al. Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[22] R. Simes,et al. An improved Bonferroni procedure for multiple tests of significance , 1986 .
[23] Tim Friede,et al. Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection , 2014, Journal of biopharmaceutical statistics.
[24] P. Bauer,et al. The risks of methodology aversion in drug regulation , 2014, Nature Reviews Drug Discovery.
[25] Martin Posch,et al. Adaptive Budgets in Clinical Trials , 2013, Statistics in biopharmaceutical research.
[26] G. Hommel. Adaptive Modifications of Hypotheses After an Interim Analysis , 2001 .
[27] Frank Bretz,et al. TUTORIAL IN BIOSTATISTICS Adaptive designs for confirmatory clinical trials , 2022 .
[28] A. Breckenridge,et al. The risks of risk aversion in drug regulation , 2013, Nature Reviews Drug Discovery.
[29] T. Friede,et al. A conditional error function approach for subgroup selection in adaptive clinical trials , 2012, Statistics in medicine.
[30] Robert A. Beckman,et al. Hypothesis Testing in a Confirmatory Phase III Trial With a Possible Subset Effect , 2009 .
[31] Lawrence D. Phillips,et al. Benefit-risk methodology project:work package 3 report: field tests , 2011 .
[32] Daniel J Sargent,et al. Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All , 2009, Journal of biopharmaceutical statistics.
[33] Nigel Stallard,et al. An Adaptive Group Sequential Design for Phase II/III Clinical Trials that Select a Single Treatment From Several , 2005, Journal of biopharmaceutical statistics.
[34] Sue-Jane Wang,et al. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset , 2007, Pharmaceutical statistics.
[35] R. Simon,et al. On the efficiency of targeted clinical trials , 2005, Statistics in medicine.
[36] R. Simon,et al. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. , 2007, Journal of the National Cancer Institute.
[37] H. Schäfer,et al. A general statistical principle for changing a design any time during the course of a trial , 2004, Statistics in medicine.
[38] H. Schäfer,et al. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches , 2001, Biometrics.
[39] Daniel J Sargent,et al. Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers , 2013, Clinical trials.
[40] Y. Hochberg. A sharper Bonferroni procedure for multiple tests of significance , 1988 .
[41] A. Egberts,et al. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements , 2013, Pharmaceutical statistics.